Fri, 25th Nov 2022 11:33
(Sharecast News) - Omega Diagnostics confirmed the receipt of deferred consideration from the sale of the CD4 business on Friday.
The AIM-traded medical diagnostics company said it had now received the £4m of deferred consideration.
"Accordingly, as of close-of-business on 24 November, Omega held cash balances of £6.5m," the board said in its short statement.
At 1116 GMT, shares in Omega Diagnostics Group were up 10.83% at 3.99p.
Reporting by Josh White for Sharecast.com.
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
(Alliance News) - Omega Diagnostics Group PLC on Tuesday said that Group Finance Director Chris Lea has stepped down with immediate effect, as he is b...
(Alliance News) - Omega Diagnostics Group PLC on Thursday said its annual loss widened as operational difficulties caused its revenue to plunge.